Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Lipids of the Human Tear Film and Their Effect on Tear Stability

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2010 by University of Louisville.
Recruitment status was:  Recruiting
Information provided by:
University of Louisville Identifier:
First received: December 1, 2008
Last updated: November 23, 2010
Last verified: June 2010
This prospective, randomized, comparative clinical trial evaluates the effect of either oral doxycycline, oral essential fatty acid, or topical azithromycin to modify the secretions of the meibomian gland in subjects with meibomian gland dysfunction and/or dry eye disease.

Condition Intervention Phase
Drug: doxycycline
Drug: essential fatty acid
Drug: azithromycin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Lipids of the Human Tear Film and Their Effect on Tear Stability

Resource links provided by NLM:

Further study details as provided by University of Louisville:

Primary Outcome Measures:
  • Inflammation of eyelid (Clinical; Phase transition temp (Laboratory) [ Time Frame: 2 months ]

Secondary Outcome Measures:
  • Character of meibomian gland secretion [ Time Frame: 2 months ]

Estimated Enrollment: 400
Study Start Date: July 2008
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Doxycycline
Oral doxycycline
Drug: doxycycline
Oral doxycycline 100mg bid
Other Name: Minocycline
Active Comparator: essential fatty acid
Oral essential fatty acid
Drug: essential fatty acid
Oral essential fatty acid 1000mg per day
Other Name: Fish Oil; Flax Seed Oil
Active Comparator: azithromycin
Topical azithromycin daily to the conjunctival culdesac
Drug: azithromycin
topical 1% azithromycin daily to eye
Other Name: Azasite

Detailed Description:
Subjects with meibomian gland dysfunction undergo expression of the meibomian gland secretion prior to beginning treatment with either oral doxycycline, oral essential fatty acids, or topical azithromycin solution. Doxycycline is dosed at 100 mg bid; essential fatty acid is dosed at 1000 mg per day; topical azithromycin is delivered once per day as a 1% solution. Treatment with doxycycline is for two months; treatment with essential fatty acids is for two months; treatment with topical azithromycin is for one month. Following treatment, meibomian glands are again expressed and the lipids measured by spectroscopy (FTIR, MALDI-TOF, NMR)for characterization of structure and function. Analysis for presence of doxcycline or azithromycin is also performed. Changes in lipid parameters are correlated with clinical signs and symptoms of disease.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Meibomian gland dysfunction

Exclusion Criteria:

  • Lid margin scarring; herpetic blepharitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00803452

Contact: Gary N Foulks, MD 502-852-6150
Contact: Douglas Borchman, PhD 502-852-7435

United States, Kentucky
Kentucky Lions Eye Center Recruiting
Louisville, Kentucky, United States, 40202
Contact: Gary N Foulks, MD    502-852-6150   
Principal Investigator: Gary N Foulks, MD         
Sponsors and Collaborators
University of Louisville
Principal Investigator: Gary N Foulks, MD University of Louisville
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Gary N. Foulks, MD, University of Louisville Identifier: NCT00803452     History of Changes
Other Study ID Numbers: lipidtearfilm
NEI RO-1- EY017094-02
Study First Received: December 1, 2008
Last Updated: November 23, 2010

Keywords provided by University of Louisville:
Meibomian gland dysfunction
Lid margin disease
essential fatty acid

Additional relevant MeSH terms:
Eyelid Diseases
Eye Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents processed this record on May 25, 2017